Introduction: Eight members of the International Parkinson's Disease and Movement Disorders Society Tic and Tourette Syndrome Study Group formed a subcommittee to discuss further barriers to practice guideline implementation. Based on expert opinion and literature review, the consensus was that practice variations continue to be quite broad and that many barriers in different clinical settings might negatively influence the adoption of the American Academy of Neurology and the European Society for the Study of Tourette Syndrome published guidelines., Objectives: 1) To identify how clinical practices diverge from the existing American Academy of Neurology and European Society for the Study of Tourette Syndrome guidelines, and 2) to identify categories of barriers leading to these clinical care gaps., Methods and Analysis: This article presents the methodology of a planned cross-sectional survey amongst healthcare professionals routinely involved in the clinical care of patients with persistent tic disorders, aimed at 1) identifying how practices diverge from the published guidelines; and 2) identifying categories of barriers leading to these clinical care gaps. Purposeful sampling methods are used to identify and recruit critical persistent tic disorders stakeholders. The analysis will use descriptive statistics., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: JMM has no conflicts that affect the content of this manuscript. In the past two years, she has received honoraria from the Tourette Association of America. In addition, she participates in research funded by the Tourette Association of America and the American Board of Psychiatry and Neurology. HS has no conflicts that affect the content of this manuscript. Dr. Sarva has done consulting work for Neuroderm, Bluerock, Novo Nordisk, and CALA Health. In addition, she has received clinical trial support from Neuroderm, Bluerock, Prevail, Covance, and NIH. IAM has no conflicts that affect the content of this manuscript. She has participated in research funded by AbbVie, Boston Scientific, Eli Lilly, Neuroderm, and Revance but has no ownership interest in any pharmaceutical company. In addition, she has received travel compensation or honoraria from the Tourette Association of America, Parkinson Foundation, Medscape, Efficient CME, and Cleveland Clinic, and royalties for writing a book with Robert Rose publishers. DM has no conflicts that affect the content of this manuscript. In the past two years, he has received personal compensation for consultancies by Roche, Sunovion, and Merz Pharmaceuticals but has no ownership interest in any pharmaceutical company. He has also received travel compensation or honoraria from the Dystonia Medical Research Foundation of Canada, Movement Disorders Society, and the American Academy of Neurology, and book royalties from Springer-Verlag and Oxford University Press. In addition, he received research support from Ipsen Corporate, Owerko Foundation, Dystonia Medical Research Foundation Canada, Parkinson Canada, and the Michael P Smith Family. DLG has received compensation for expert testimony for the U.S. National Vaccine Injury Compensation Program through the Department of Health and Human Services. He has received payment for medical expert opinions through Advanced Medical/Teladoc. He has served as a consultant for Applied Therapeutics, Eumentics Therapeutics, and Emalex. He has received research support from the NIH and the DOD. He has received salary compensation through Cincinnati Children’s for work as a clinical trial site investigator from Emalex (clinical trial, Tourette Syndrome) and EryDel (clinical trial, Ataxia Telangiectasia). He has received book/publication royalties from Elsevier, Wolters Kluwer, and the Massachusetts Medical Society. TP has no commercial or financial relationships that could be construed as a potential conflict of interest. TP receives research support from Alberta Health, the Alberta Children’s Hospital Research Institute, and the Public Health Agency of Canada. KJB has no conflicts that affect the content of this manuscript. In the past two years, author KJB consulted for SK Life Science, Inc., served as faculty for CME programs by Medscape and Mededicus, and served as an expert rater for the Huntington Study Group, which had contracted with Neurocrine Biosciences. In addition, his institution received research funding from Emalex Biosciences for treatment studies with ecopipam. CG has no conflicts that affect the content of this manuscript. A Freigeist Fellowship of the Volkswagen Stiftung supports him. He has received honoraria from the Movement Disorder Society and BIAL for educational activities. He received honoraria from Biomarine Pharmaceuticals as Ad Hoc Advisory Board. This does not alter our adherence to PLOS ONE policies on sharing data and materials., (Copyright: © 2023 Martindale et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.) more...